查看購物車
  • Simplified Chinese
  • English
  • Japanese
遺傳性血管性水腫市場—按治療類型和地區分類的全球和區域分析—分析與預測（2025-2035）
市場調查報告書
商品編碼
1734252

遺傳性血管性水腫市場—按治療類型和地區分類的全球和區域分析—分析與預測（2025-2035）

Hereditary Angioedema Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球遺傳性血管性水腫市場目前正處於其生命週期的成長階段。

這一階段的特點是治療選擇越來越多，包括獲得監管部門核准的新型生物療法和預防療法。人們對遺傳性血管性水腫的認知不斷提高、診斷方法的改進以及 C1 酯酶抑制劑和緩激肽受體拮抗劑等先進治療藥物的引入正在推動市場擴張。此外，對個人化醫療和預防醫療的日益關注也促進了市場的成長。儘管治療費用高和患者人數有限等挑戰依然存在，但治療方案的持續創新和市場進入的擴大預計將在未來幾年維持市場成長。

影響

  • 預計遺傳性血管性水腫治療需求的不斷成長將在 2025-2035 年預測期內支持全球遺傳性血管性水腫市場的成長。
  • 由於診斷技術的進步、創新治療方法的市場推出以及患者和醫療保健提供者意識的提高，全球遺傳性血管性水腫市場預計將顯著成長。

由於其先進的醫療保健基礎設施、高盛行率以及對該疾病的認知不斷提高，預計北美將在預測期內主導全球遺傳性血管性水腫市場。該地區還擁有良好的監管地位和強大的製藥公司，為有效治療方法的普及提供了便利，推動了全球遺傳性血管性水腫市場的成長。

近期動態

  • 監管活動：2025 年 2 月，EMA 額外批准 TAKIHIRO（通用名：lanadelumab），用於 2 mL預填充筆，為患有遺傳性血管性水腫 (HAE) 的青少年（12 歲及以上）和成年患者進行皮下核准。
  • 監管活動 2025 年 2 月，CSL Behring 在日本獲得核准，可使用 Andenbry（galadacimab）皮下注射 200 毫克筆用於預防急性遺傳性血管性水腫發作。
  • 監管活動 2025 年 1 月，KalVista Pharmaceuticals, Inc. 的 sevetralstat 獲得厚生勞動省頒發的孤兒藥稱號。
  • 監管活動 2024 年 11 月，FDA 接受了 Ionis Pharmaceuticals 的 donidalorsen新藥認證申請，用於預防性治療遺傳性血管性水腫。

需求——促進因素與限制因素

推動全球遺傳性血管性水腫市場的關鍵因素是：

  • 提高認知和早期診斷
  • 治療方案的持續進步
  • 改進的基因檢測和診斷
  • 遺傳性血管性水腫盛行率不斷上升

由於以下挑戰，全球遺傳性血管性水腫市場預計還將面臨一些限制：

  • 醫療費用高昂
  • 開發中地區獲取治療的挑戰

產品/創新策略：全球遺傳性血管性水腫市場的產品發布和創新專注於推進治療方案以改善患者護理。這些創新旨在提高治療方法效果並簡化疾病的檢測和管理。市場上的主要參與企業如 Ionis Pharmaceuticals、工業和 CSL Behring 都參與開發遺傳性血管性水腫的治療方法。

競爭策略：主要關注全球遺傳性血管性水腫市場領導者的公司正在不斷透過創新治療方法更新產品系列以保持競爭力。它對主要參與者進行了詳細的競爭基準化分析，深入了解了這些公司在產品供應、市場佔有率和創新方面的比較。透過這種基準化分析，讀者可以清楚地了解市場格局和主要企業的地位。此外，包括夥伴關係、協議和聯盟在內的綜合競爭策略可協助讀者發現市場中尚未開發的商機。

主要市場參與企業及競爭格局

公司簡介是根據從主要專家收集的資訊以及透過分析公司覆蓋範圍、產品系列和市場滲透率來選擇的。

本報告研究了全球遺傳性血管性水腫市場，並概述了市場以及治療類型、地理位置和公司概況的趨勢。

目錄

執行摘要

第1章全球遺傳性血管性水腫市場：產業展望

  • 市場概況與生態系統
  • 市場趨勢
  • 遺傳性血管性水腫的流行病學分析
    • 按地區
  • 臨床試驗
    • 愛別
    • 依贊助商類型
  • 監管狀況/合規性
    • 美國法律要求與框架
    • 歐盟法律要求和框架
    • 亞太地區的法律要求與框架
  • 市場動態
    • 影響分析
    • 市場促進因素
    • 市場限制
    • 市場機會

2. 全球遺傳性血管性水腫市場（依治療類型分類），百萬美元，2023-2035 年

  • C1酯酶抑制劑
  • 緩激肽B2受體拮抗劑
  • 激肽釋放酶抑制劑
  • 其他

3. 全球遺傳性血管性水腫市場（按地區分類），百萬美元，2023-2035 年

  • 北美洲
  • 歐洲
  • 亞太地區

4. 全球遺傳性血管性水腫市場競爭基準化分析與公司概況

  • 競爭格局
    • 各公司主要策略及發展
    • 關鍵進展
  • 公司簡介
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Ionis Pharmaceuticals, Inc.
    • Pharming Group
    • BioCryst Pharmaceuticals
    • KalVista Pharmaceuticals
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • Octapharma

第5章調查方法

Product Code: BHL2879SA

Market Lifecycle Stage

The global hereditary angioedema market is currently in the growth stage of its lifecycle. This phase is characterized by an increasing number of treatment options, including novel biologic therapies and prophylactic treatments, which are gaining regulatory approvals. The market is experiencing expansion driven by the rising awareness of hereditary angioedema, improved diagnostic methods, and the introduction of advanced therapies such as C1 esterase inhibitors and bradykinin receptor antagonists. Additionally, the growing focus on personalized medicine and preventive care is contributing to the growth of the market. Although challenges such as high treatment costs and a limited patient population remain, the ongoing innovation in treatment options and expanding market access are expected to sustain the market's growth in the coming years.

Impact

  • Increasing demand for hereditary angioedema therapies is anticipated to support the growth of the global hereditary angioedema market during the forecast period 2025-2035.
  • The global hereditary angioedema market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Therapy Type

  • C1-esterase inhibitor
  • Bradykinin B2 receptor antagonist
  • Kallikrein inhibitor
  • Others

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

North America is expected to dominate the global hereditary angioedema market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hereditary angioedema market.

Recent Developments

  • Regulatory Activities: In February 2025, EMA approved an additional 2 mL pre-filled pen option for TAKHZYRO (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (HAE).
  • Regulatory Activities: In February 2025, CSL Behring secured regulatory approval in Japan for Andembry (garadacimab) subcutaneous injection 200mg Pens for the prevention of acute hereditary angioedema attacks.
  • Regulatory Activities: In January 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to KalVista Pharmaceuticals, Inc.'s sebetralstat.
  • Regulatory Activities: In November 2024, the FDA accepted the new drug application for Ionis Pharmaceuticals' donidalorsen for the prophylactic treatment of hereditary angioedema.

Demand - Drivers and Limitations

The following are the drivers for the global hereditary angioedema market:

  • Increasing Awareness and Early Diagnosis
  • Continuous Advancements in Treatment Options
  • Improved Genetic Testing and Diagnosis
  • Increasing Prevalence of Hereditary Angioedema

The global hereditary angioedema market is expected to face some limitations, too, due to the following challenges:

  • High Treatment Costs
  • Challenges in Accessing Treatments in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hereditary angioedema market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Ionis Pharmaceutical, Takeda, and CSL Behring, have been involved in the development of therapies for hereditary angioedema.

Competitive Strategy: Enterprises led by market leaders in the global hereditary angioedema market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Adverum Biotechnologies, Inc.
  • Attune Pharmaceuticals
  • BioCryst Pharmaceuticals
  • CSL Behring
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals
  • Octapharma
  • Pharming Group
  • Takeda Pharmaceutical Company Limited

Table of Contents

Executive Summary

Scope of Study

1. Global Hereditary Angioedema Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
  • 1.2 Market Trends
  • 1.3 Epidemiological Analysis of Hereditary Angioedema
    • 1.3.1 By Region
  • 1.4 Clinical Trials
    • 1.4.1 By Phase
    • 1.4.2 By Sponsor Type
  • 1.5 Regulatory Landscape / Compliance
    • 1.5.1 Legal Requirement and Framework in the U.S.
    • 1.5.2 Legal Requirement and Framework in the E.U.
    • 1.5.3 Legal Requirement and Framework in Asia-Pacific
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Hereditary Angioedema Market, By Therapy Type, $Million, 2023-2035

  • 2.1 C1-esterase inhibitor
  • 2.2 Bradykinin B2 receptor antagonist
  • 2.3 Kallikrein inhibitor
  • 2.4 Others

3. Global Hereditary Angioedema Market, By Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Market Dynamics
    • 3.1.2 Market Sizing and Forecast
      • 3.1.2.1 North America Hereditary Angioedema Market (by Country)
        • 3.1.2.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Market Dynamics
    • 3.2.2 Market Sizing and Forecast
      • 3.2.2.1 Europe Hereditary Angioedema Market (by Country)
        • 3.2.2.1.1 U.K.
        • 3.2.2.1.2 Germany
        • 3.2.2.1.3 France
        • 3.2.2.1.4 Italy
        • 3.2.2.1.5 Spain
  • 3.3 Asia-Pacific
    • 3.3.1 Market Dynamics
    • 3.3.2 Market Sizing and Forecast
      • 3.3.2.1 Asia-Pacific Hereditary Angioedema Market (by Country)
        • 3.3.2.1.1 Japan

4. Global Hereditary Angioedema Market - Competitive Benchmarking and Company Profiles

  • 4.1 Competitive Landscape
    • 4.1.1 Key Strategies and Developments by Company
      • 4.1.1.1 Funding Activities
      • 4.1.1.2 Mergers and Acquisitions
      • 4.1.1.3 Regulatory Approvals
      • 4.1.1.4 Partnerships, Collaborations and Business Expansions
    • 4.1.2 Key Developments Analysis
  • 4.2 Company Profiles
    • 4.2.1 Takeda Pharmaceutical Company Limited
      • 4.2.1.1 Company Overview
      • 4.2.1.2 Product Portfolio
      • 4.2.1.3 Target Customers/End Users
      • 4.2.1.4 Analyst View
    • 4.2.2 CSL Behring
      • 4.2.2.1 Company Overview
      • 4.2.2.2 Product Portfolio
      • 4.2.2.3 Target Customers/End Users
      • 4.2.2.4 Analyst View
    • 4.2.3 Ionis Pharmaceuticals, Inc.
      • 4.2.3.1 Company Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers/End Users
      • 4.2.3.4 Analyst View
    • 4.2.4 Pharming Group
      • 4.2.4.1 Company Overview
      • 4.2.4.2 Product Portfolio
      • 4.2.4.3 Target Customers/End Users
      • 4.2.4.4 Analyst View
    • 4.2.5 BioCryst Pharmaceuticals
      • 4.2.5.1 Company Overview
      • 4.2.5.2 Product Portfolio
      • 4.2.5.3 Target Customers/End Users
      • 4.2.5.4 Analyst View
    • 4.2.6 KalVista Pharmaceuticals
      • 4.2.6.1 Company Overview
      • 4.2.6.2 Product Portfolio
      • 4.2.6.3 Target Customers/End Users
      • 4.2.6.4 Analyst View
    • 4.2.7 Attune Pharmaceuticals
      • 4.2.7.1 Company Overview
      • 4.2.7.2 Product Portfolio
      • 4.2.7.3 Target Customers/End Users
      • 4.2.7.4 Analyst View
    • 4.2.8 Adverum Biotechnologies, Inc.
      • 4.2.8.1 Company Overview
      • 4.2.8.2 Product Portfolio
      • 4.2.8.3 Target Customers/End Users
      • 4.2.8.4 Analyst View
    • 4.2.9 Octapharma
      • 4.2.9.1 Company Overview
      • 4.2.9.2 Product Portfolio
      • 4.2.9.3 Target Customers/End Users
      • 4.2.9.4 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Hereditary Angioedema Market, Epidemiological Analysis, U.S.
  • Figure: Global Hereditary Angioedema Market Coverage
  • Figure: Global Hereditary Angioedema Market Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Hereditary Angioedema Market, Competitive Landscape, January 2022-April 2025

List of Tables

  • Table: Global Hereditary Angioedema Market, Regulatory Scenario
  • Table: Global Hereditary Angioedema Market Dynamics, Impact Analysis
  • Table: Global Hereditary Angioedema Market (by Therapy Type), $Million, 2023-2035
  • Table: Global Hereditary Angioedema Market (by Region), $Million, 2023-2035